HPV Information - Research Projects
The Lombardi Cancer Center's Division of Cancer Prevention and Control is presently conducting three studies to eradicate, or ameliorate the effects of HPV.
- The first is a clinical trial to test the effectiveness of a new oral medication (that is, swallowing like a vitamin) to treat ano-genital HPV warts. This study is anticipated to be open for enrollment in Summer 2000 in four US cities (Washington, DC; New Haven, CT; San Francisco; New York City).
- The second study looks at the costs and benefits of using new tests to detect HPV as an adjunct to Pap smears to screen for cervical cancer.
- Since cervical cancer is the second leading cancer cause of death in women worldwide, we are also conducting a third research project to assess the costs and benefits of several alternative approaches to screen for pre-cursors of cervical cancer in under-developed countries.
Courtesy of - Lombardi Cancer Center
Yahoo Health - Sexually Transmitted Diseases
- Source
HPV Information - New Treatments On The Horizon
On the horizon are activities that spell good news in the fight against cervical cancer:
HPV Information - Improving the Pap test
Engineers, scientists, and physicians are working together to improve the way cervical cell samples are collected and analyzed during a Pap test. Other researchers are evaluating new ways to manage women with mildly abnormal Pap tests. The results of this research will help women and their physicians to decide what to do when a Pap test appears to be abnormal.
Nice To Know:
The number of new cervical cancer diagnoses and the number of cervical cancer deaths decline each year. Experts believe these statistics would decline even more rapidly if regular Pap tests were given to all women who are or have been sexually active or have reached the age of 18.
HPV Information - Developments In Human Papilloma Virus (HPV) Research
Researchers are now developing simple and inexpensive laboratory tests that are capable of detecting cancer-causing strains of human papillomavirus (HPV). Such tests eventually will be available for widespread, routine use. In addition, researchers are in the process of creating vaccines that will:
- Destroy HPV before the virus is firmly established
- Produce an immune system response that kills or stops the growth of cancer cells that have spread beyond the cervix
Improvements are also being made in HPV screening tests, which will identify women with HPV-related and cancer-related changes in cervical cells.
HPV Information - Clinical Trials And Other Research
Clinical trials - studies that evaluate the effectiveness of new drugs and other treatments in a controlled, clinical setting - are now underway in select groups of patients. These cervical cancer trials should help to determine the value of the latest anti-cancer therapies, such as:
- New chemotherapy medications
- Radiation techniques
- Combination therapies (for example, surgery plus radiation or chemotherapy)
In addition, cancer researchers are now studying the ways that oncogenes (genes that contribute to cancer) and tumor suppressor genes (genes that hinder tumor development) regulate cell growth and cause normal cervical cells to become malignant (cancerous). The goal is to learn how to stop abnormal cell growth by replacing damaged genes in cancer cells with normal genes.
Provided by YourMedicalSource.com
Last Reviewed: 2002 by YourMedicalSource.com
A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Laura A. Koutsky, Ph.D., Kevin A. Ault, M.D., Cosette M. Wheeler, Ph.D., Darron R. Brown, M.D., Eliav Barr, M.D., Frances B. Alvarez, R.N., Lisa M. Chiacchierini, Ph.D., Kathrin U. Jansen, Ph.D., for the Proof of Principle Study Investigators
HPV Information - ABSTRACT
Background Approximately 20 percent of adults become infected with human papillomavirus type 16 (HPV-16). Although most infections are benign, some progress to anogenital cancer. A vaccine that reduces the incidence of HPV-16 infection may provide important public health benefits.
Methods In this double-blind study, we randomly assigned 2392young women (defined as females 16 to 23 years of age) to receive three doses of placebo or HPV-16 virus-like-particle vaccine (40 µg per dose), given at day 0, month 2, and month 6.Genital samples to test for HPV-16 DNA were obtained at enrollment, one month after the third vaccination, and every six months thereafter. Women were referred for colposcopy according to a protocol. Biopsy tissue was evaluated for cervical intraepithelialneoplasia and analyzed for HPV-16 DNA with use of the polymerasechain reaction. The primary end point was persistent HPV-16infection, defined as the detection of HPV-16 DNA in samples obtained at two or more visits. The primary analysis was limited to women who were negative for HPV-16 DNA and HPV-16 antibodiesat enrollment and HPV-16 DNA at month 7.
Results The women were followed for a median of 17.4 months after completing the vaccination regimen. The incidence of persistentHPV-16 infection was 3.8 per 100 woman-years at risk in the placebo group and 0 per 100 woman-years at risk in the vaccine group (100 percent efficacy; 95 percent confidence interval, 90 to 100; P<0.001). All nine cases of HPV-16-related cervical intraepithelial neoplasia occurred among the placebo recipients.
Conclusions Administration of this HPV-16 vaccine reduced the incidence of both HPV-16 infection and HPV-16-related cervical intraepithelial neoplasia. Immunizing HPV-16-negative women may eventually reduce the incidence of cervical cancer.
HPV Information - Source Information
From the Department of Epidemiology, University of Washington, Seattle (L.A.K.); the Department of Obstetrics and Gynecology, University of Iowa, Iowa City (K.A.A.); the Department of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque (C.M.W.); the Department of Medicine, Indiana University School of Medicine, Indianapolis (D.R.B.); Biologics Clinical Research (E.B., F.B.A.) and the Department of Biostatistics (L.M.C.), Merck Research Laboratories, Blue Bell, Pa.; and the Department of Virus and Cell Biology, Merck Research Laboratories, West Point, Pa. (K.U.J.).
Original Article:ÿ Volume 347:1645-1651, November 21, 2002, Number 21
Vocaturo A, Marandino E, Celata E, Caffo A, Moauro M, Vocaturo G, Perrone Donnorso R.
Colourimetric signal amplification of in situ hybridization assay for human papillomavirus DNA detection in cytological samples.
J Exp Clin Cancer Res. 2002 Jun;21(2):239-46.
PMID: 12148585 [PubMed - in process]
Butler D, Collins C, Mabruk M, Leader MB, Kay EW.
Loss of Fhit expression as a potential marker of malignant progression in preinvasive squamous cervical cancer.
Gynecol Oncol. 2002 Aug;86(2):144-9.
PMID: 12144820 [PubMed - indexed for MEDLINE]
Ammatuna P, Campisi G, Giovannelli L, Giambelluca D, Alaimo C, Mancuso S, Margiotta V.
Presence of Epstein-Barr virus, cytomegalovirus and human papillomavirus in normal oral mucosa of HIV-infected and renal transplant patients.
Oral Dis. 2001 Jan;7(1):34-40.
PMID: 11354920 [PubMed - indexed for MEDLINE]
Above research excerpts courtesy of PubMed
- National Library of Medicine
